Overview

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain. The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide